Eli Lilly (NYSE:LLY) said on Thursday that the European Commission has granted marketing authorization for Kisunla (donanemab) for the treatment of early symptomatic Alzheimer’s disease in adults with mild cognitive impairment as well as those with mild dementia stages.
The Kisunla marketing authorization in the European Union is based on the TRAILBLAZER-ALZ 2 and the TRAILBLAZER-ALZ 6 clinical trials.
The Phase 3 TRAILBLAZER-ALZ 2 study demonstrated Kisunla significantly slowed cognitive and functional decline.
